Rifampicin (Rifadin) tab 300 mg: Supply issue resolved

Sanofi was out of stock of Rifampicin tab 300 mg due to an equipment problem at the manufacturing facility.

20 November 2024 update

Normal supply of Rifadin (rifampicin tab 300 mg, Pharmacode 251194) has resumed. Stock has been released to wholesalers.  

Affected product

Because of an issue with equipment at the manufacturing facility, Sanofi was out of stock of rifampicin tab 300 mg.

  • Chemical: Rifampicin
  • Presentation: Cap 300 mg
  • Brand: Rifadin
  • Pharmacode: 251194 
  • Subsidy: $122.06
  • Measure / Qty: per 100

Alternate product listed

Sanofi arranged alternative stock from the United Kingdom. Sanofi advise that Medsafe has granted a labelling exemption for this product. Pharmac will de-list this product from the Pharmaceutical Schedule in due course to allow time for stock of the product to be dispensed and claimed for.

Medsafe product approval detail(external link)

  • Brand: Rifadin Sanofi 
  • Pharmacode: 2669838 
  • Subsidy: $122.06
  • Measure / Qty: per 100

Schedule listing for rifampicin(external link)

Rifadin Datasheet - Medsafe website [PDF](external link)

Resupplied November 2024

Sanofi advise that stock of their New Zealand registered product is arriving and being distributed to wholesalers. Please note that wholesalers may ask that the alternative product be supplied until stock is depleted.

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.  

Sign up to our email list for regular emails about supply issues and more(external link)